Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 years.

Autor: Vega-Piris L; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain. Electronic address: lorena.vega@isciii.es., Carretero SG; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain., Mayordomo JL; General University Hospital Consortium of Valencia, Valencian Community, Spain., Zarzuelo MBR; Directorate General of Public Health, Regional Ministry of Health of Madrid, Madrid, Spain., Río VÁ; Epidemiology Service, Healthcare Department, General Directorate of Public Health, Castilla y León, Spain., García VG; Occupational Health and Surveillance Service, Directorate General of Public Health and Pharmaceutical Regulation, Ministry of Health and Consumer of Andalucía, Andalucía, Spain., Vázquez MG; Epidemiological Surveillance, Directorate General of Public Health, Department of Health, Government of Aragón, Zaragoza, Spain., Rodríguez MDCG; Epidemiological Surveillance, Directorate General of Public Health, Extremadura Health Service, Mérida, Spain., Basile L; Public Health Agency of Catalonia, Department of Health, Barcelona, Spain., González-Coviella NL; Epidemiological Surveillance Unit of the Directorate General of Public Health of the Canary Health Service, Canary Islands, Spain., Boada MIB; Epidemiology Service, Health Department, General Directorate of Public Health and Addictions, Murcia Region, Spain., Pérez-Martínez O; Epidemiology Service, Directorate General of Public Health, Ministry of Health, Regional Government of Galicia, Santiago, Spain., Azevedo AL; Public Health Directorate General, Health Department, Valencia, Spain., Rubio CQ; Epidemiology and Health Prevention Service, Directorate General of Public Health, Consumer and Care of La Rioja, Logroño, Spain., Duran JG; Epidemiology Service, Directorate General of Public Health, Balearic Islands, Spain; Health Research Institute of the Balearic Islands (IdISBa), Spain., Ibáñez AF; Epidemiological Surveillance Service, Public Health Asturias, Spain., Rivera MVG; Epidemiology Service Technician, General Directorate of Public Health, Ministry of Health of Castilla La Mancha, Spain., Marín VR; Department of Epidemiological Surveillance, Council of Health, Ceuta, Spain., Castrillejo D; Epidemiological Surveillance, Ministry of Social Policies and Public Health of Melilla, Directorate General of Public Health, Melilla, Spain., Raymundo LJV; Epidemiological Surveillance Section, General Directorate of Public Health, Ministry of Health of Cantabria, Spain., Larrauri A; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain; CIBER on Epidemiology and Public Health, Madrid, Spain., Monge S; Department of Communicable Diseases, National Centre of Epidemiology, Institute of Health Carlos III, Madrid, Spain; CIBER on Infectious Diseases, Madrid, Spain.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2024 Nov; Vol. 89 (5), pp. 106292. Date of Electronic Publication: 2024 Sep 26.
DOI: 10.1016/j.jinf.2024.106292
Abstrakt: Introduction: Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19.
Methods: We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities. We stratified the estimates by vaccination status for influenza or SARS-CoV2.
Results: Among patients unvaccinated for influenza or SARS-CoV-2, those with RSV had similar or lower risk of pneumonia [vs. influenza: RR= 0.91 (95% Confidence Interval: 0.72-1.16); vs. SARS-CoV-2: 0.81 (0.67-0.98)], ICU admission [vs. influenza: 0.93 (0.41-2.08); vs. SARS-CoV-2: 1.10 (0.61-1.99)] and mortality [vs. influenza: 0.64 (0.32-1.28); vs. SARS-CoV-2: 0.56 (0.30-1.04)]. Among the vaccinated, results were largely similar except for a higher risk of ICU admission with RSV [vs. influenza: 2.13(1.16-3.89); vs. SARS-CoV-2: 1.83 (1.02-3.28)] CONCLUSIONS: RSV presented similar or lower intrinsic severity than influenza or SARS-CoV2. Among vaccinated patients, RSV was associated to higher ICU-admission, suggesting the potential for preventive RSV vaccination.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: